Zolbetuximab (development code IMAB362) is an experimental monoclonal antibody against isoform 2 of Claudin-18. It is under investigation for the treatment of gastrointestinal adenocarcinomas and pancreatic tumors. IMAB362 was developed by Ganymed Pharmaceuticals AG. The drug is in phase III clinical trials as of November 2021. Preliminary results from the phase II 'FAST' trial in June 2016 suggest it is helpful for advanced gastric cancer.
Attributes | Values |
---|---|
rdf:type | |
rdfs:label |
|
rdfs:comment |
|
dcterms:subject | |
Wikipage page ID |
|
Wikipage revision ID |
|
Link from a Wikipage to another Wikipage | |
sameAs | |
dbp:wikiPageUsesTemplate | |
ATC prefix |
|
CAS number |
|
ChemSpiderID |
|
legal status |
|
source |
|
synonyms |
|
target |
|
type |
|
UNII |
|
Verifiedfields |
|
verifiedrevid |
|
has abstract |
|
mab type |
|
prov:wasDerivedFrom | |
page length (characters) of wiki page |
|
CAS number |
|
FDA UNII code |
|
foaf:isPrimaryTopicOf | |
is Link from a Wikipage to another Wikipage of | |
is Wikipage redirect of | |
is foaf:primaryTopic of |